SCHEMBL10242991

SCHEMBL10242991

CCCCC(=O)Nc1cccc(-c2ccco2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.60
HPGD P15428 4/20 0.60
TSHR P16473 3/20 0.60
USP2 O75604 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
ALDH1A1 P00352 6/20 0.55
KDM4E B2RXH2 4/20 0.54
PTPN1 P18031 1/20 0.54
PTPRA P18433 1/20 0.54
LMNA P02545 4/20 0.54
MAPT P10636 3/20 0.53
HSD17B10 Q99714 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
MAPK1 P28482 1/20 0.53
RAB9A P51151 1/20 0.51
MAPK10 P53779 1/20 0.51
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243023 0.82 PTPN7 (0.64) HPGDUSP2ALDH1A1KDM4EMAPT
SCHEMBL10969527 0.80 KDM4E (0.72) SMN1; SMN2HPGDTSHRUSP2NPSR1
SCHEMBL10115339 0.80 HDAC6 (0.53) SMN1; SMN2HPGDTSHRUSP2NPSR1
SCHEMBL10115485 0.80 HDAC6 (0.53) SMN1; SMN2HPGDTSHRUSP2NPSR1
SCHEMBL4320689 0.78 KEAP1 (0.59) SMN1; SMN2HPGDTSHRNPSR1ALDH1A1
SCHEMBL6037980 0.77 HDAC6 (0.74) SMN1; SMN2HPGDTSHRUSP2NPSR1
SCHEMBL28453595 0.76 ALDH1A1 (0.48) SMN1; SMN2HPGDALDH1A1KDM4ELMNA
SCHEMBL11901010 0.76 LMNA (0.69) SMN1; SMN2ALDH1A1KDM4ELMNAMEN1
SCHEMBL11043355 0.75 HDAC3 (0.63) SMN1; SMN2HPGDTSHRUSP2NPSR1
SCHEMBL29563496 0.75 HDAC3 (0.75) HPGDALDH1A1KDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 SMN1; SMN2 3120/4885HPGD 556/4885TSHR 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.